Based in Boston and Geneva, Alys Pharmaceuticals is an immuno-dermatology-focused company founded by merging six asset-centric Medicxi companies. Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. Alys has started off with a $100 million investment from Medicxi..

Alys Pharmaceuticals总部位于波士顿和日内瓦，是一家专注于免疫皮肤病的公司，由六家以资产为中心的Medicxi公司合并而成。Alys拥有针对多种皮肤病适应症的强大创新计划和平台。Alys从Medicxi的一亿美元投资开始。。

Founded by consolidating six existing Medicxi biotech firms, Alys Pharmaceuticals aims to transform the treatment paradigm for several dermatology conditions. The company combines the assets and platforms of Aldena Therapeutics, Granular Therapeutics, Klirna Biotech – which have an affiliate in Switzerland and a significant portion of their staff based in Switzerland – as well as Graegis Pharmaceuticals, Nira Biosciences and Vimela Therapeutics..

Alys Pharmaceuticals通过整合六家现有的Medicxi生物技术公司成立，旨在改变几种皮肤病的治疗模式。该公司整合了Aldena Therapeutics、Granular Therapeutics、Klirna Biotech的资产和平台，该公司在瑞士设有分支机构，大部分员工位于瑞士，以及Graegis Pharmaceuticals、Nira Biosciences和Vimela Therapeutics。。

The newly formed company boasts a pipeline of 14 active programs targeting indications such as atopic dermatitis, vitiligo, psoriasis and mastocytosis. Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

这家新成立的公司拥有14个针对特应性皮炎、白癜风、牛皮癣和肥大细胞增多症等适应症的积极项目。艾利斯认为，新出现的适应症，如特应性皮炎、白癜风、斑秃和慢性自发性荨麻疹，将在皮肤病学方面取得新的突破。

The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies..

该管道还包括专注于服务不足的适应症的项目，例如肥大细胞增多症，皮肤T细胞淋巴瘤或预防肿瘤治疗的皮肤副作用。。

Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses. Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies..

Alys预计其尖端平台将进一步发展有机管道，涵盖炎症性疾病，自身免疫性疾病，癌症患者和罕见皮肤病的皮肤病支持治疗。在接下来的三年中，该公司的目标是提供7到10个临床概念验证（POC）读数，并可能至少有一个计划推进注册研究。。

Operations and team in SwitzerlandWith the incorporation in Switzerland underway, Alys operations will also be conducted in Switzerland, with activities covering the entire spectrum of biotech work, from general management, finance, R&D, medical, and regulatory examples. One of Alys’ affiliates (Aldena Therapeutics) also has an active collaboration with EMPA (Swiss Federal Laboratories for Materials Science & Technology) under an Innosuisse grant, to develop one of its core technologies..

瑞士的运营和团队随着在瑞士的成立，Alys的运营也将在瑞士进行，其活动涵盖了从综合管理、财务、研发、医疗和监管等各个方面的生物技术工作。Alys的一个附属公司（Aldena Therapeutics）也在Innosuisse资助下与EMPA（瑞士联邦材料科学与技术实验室）积极合作，开发其核心技术之一。。

Moreover, Alys's team comprises 8-10 full-time employees based in Switzerland alone, and “this will increase as our programs progress forward. Alys in Switzerland is also supported by a significant number of Swiss-based consultants and Swiss-based R&D service companies with staff employed by Alys and affiliates”, says Lausanne-based Thibaud Portal, formerly Galderma’s Global Head of Prescription Medicines.

此外，仅在瑞士，Alys的团队就有8-10名全职员工，并且“随着我们项目的进展，这一数字会增加。瑞士的Alys还得到了大量瑞士顾问和瑞士研发服务公司的支持，其员工均由Alys及其附属公司雇用”，洛桑的Thibaud Portal表示，曾任高德玛处方药全球负责人。

Alongside being the co-founder, Portal is assuming the role of COO to run Alys..

除了担任联合创始人外，门户网站还担任运营ALIS的首席运营官。。

World-leading dermatology experts to fuel Alys’ development Co-founded by Medicxi and several world-leading dermatology and scientific experts, Besides Portal is a top-notch team that includes co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), Alys aspires to redefine the landscape of dermatological treatments..

世界领先的皮肤病专家推动了艾利斯的发展，由Medicxi和几位世界领先的皮肤病学和科学专家共同创立，此外，门户网站是一支顶尖的团队，其中包括联合创始人约翰·哈里斯（麻省大学陈医学院）、布莱恩·金（西奈山伊坎医学院）、拉尔斯·弗伦奇（慕尼黑大学）、诺贝尔奖获得者克雷格·梅洛（麻省大学陈医学院），埃里克·德伊奇（古斯塔夫·鲁西饰）和马克·普劳斯尼茨（乔治亚理工学院饰），艾利斯立志重新定义皮肤病治疗领域。。

Alys is working with leading institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology, demonstrating its commitment to collaborative research and development..

Alys正在与领先机构合作，如古斯塔夫·鲁西研究所、麻省大学陈医学院、西奈山伊坎医学院、佐治亚理工学院和Empa、瑞士联邦材料科学与技术实验室，表明其对合作研究和开发的承诺。。

$100 million for Alys Alys is backed by international investment firm Medicxi with $100M financing. Francesco De Rubertis, Partner at Medicxi, who will assume the role of Chairman of Alys Pharmaceutical said: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology.

Alys Alys的1亿美元资金由国际投资公司Medicxi提供，融资1亿美元。将担任Alys Pharmaceutical董事长的Medicxi合伙人Francesco De Rubertis表示：“我们相信，将多家以资产为中心的公司与一个非凡的团队聚集在一起，将推动Alys转变免疫皮肤病学的创新。

Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”(Press release/RAN)image stefamerpik on FreePik.

Alys管理着广泛的资产管道，具有不同的风险状况，并将从规模的变化和便利的资本获取中受益匪浅。”（新闻稿/RAN）在FreePik上拍摄stefamerpik。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送